The Impact of COVID-19 on Hospitalised COPD Exacerbations in Malta.

Method: Data was collected retrospectively from electronic hospital records during the periods 1st March until 10th May in 2019 and 2020.

Results: There was a marked decrease in AECOPD admissions in 2020, with a 54.2% drop in admissions ( n = 119 in 2020 vs. n = 259 in 2019). There was no significant difference in patient demographics or medical comorbidities. In 2020, there was a significantly lower number of patients with AECOPD who received nebulised medications during admission (60.4% in 2020 vs. 84.9% in 2019; p ≤ 0.001). There were also significantly lower numbers of AECOPD patients admitted in 2020 who received controlled oxygen via venturi masks (69.0% in 2020 vs. 84.5% in 2019; p = 0.006). There was a significant increase in inpatient mortality in 2020 (19.3% [ n = 23] and 8.4% [ n = 22] for 2020 and 2019, respectively, p = 0.003). Year was found to be the best predictor of mortality outcome ( p = 0.001). The lack of use of SABA pre-admission treatment ( p = 0.002), active malignancy ( p = 0.003), and increased length of hospital stay ( p = 0.046) were also found to be predictors of mortality for AECOPD patients; however, these parameters were unchanged between 2019 and 2020 and therefore could not account for the increase in mortality.

Conclusions: There was a decrease in the number of admissions with AECOPD in 2020 during the COVID-19 pandemic, when compared to 2019. The year 2020 proved to be a significant predictor for inpatient mortality, with a significant increase in mortality in 2020. The decrease in nebuliser and controlled oxygen treatment noted in the study period did not prove to be a significant predictor of mortality when corrected for other variables. Therefore, the difference in mortality cannot be explained with certainty in this retrospective cohort study.